{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Treatment+-+Cohort+3&page=23", "query": { "intervention": "Combination Treatment - Cohort 3", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 1069, "total_pages": 107, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Treatment+-+Cohort+3&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Treatment+-+Cohort+3&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T20:42:49.001Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02896335", "title": "Palbociclib and Pembrolizumab In Central Nervous System Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Malignant Neoplasm to Brain", "Recurrent Brain Metastases", "Progressive Brain Metastases" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2017-02-02", "completion_date": "2029-09-01", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-15T20:42:49.001Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02896335" }, { "nct_id": "NCT05650879", "title": "ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2 Mutant Non-small Cell Lung Cancer", "HER2-positive Metastatic Breast Cancer", "HER2 Gene Mutation", "HER2 Amplification" ], "interventions": [ { "name": "ELVN-002", "type": "DRUG" }, { "name": "Fam-Trastuzumab Deruxtecan-Nxki", "type": "DRUG" }, { "name": "Trastuzumab emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Enliven Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 198, "start_date": "2023-03-20", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2025-07-15", "last_synced_at": "2026-10-15T20:42:49.001Z", "location_count": 5, "location_summary": "Aurora, Colorado • Orlando, Florida • Plantation, Florida + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Plantation", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05650879" }, { "nct_id": "NCT03743662", "title": "Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Re-irradiation (RT)", "type": "RADIATION" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Re-resection", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2018-11-12", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-10-15T20:42:49.001Z", "location_count": 11, "location_summary": "Hartford, Connecticut • Indianapolis, Indiana • Basking Ridge, New Jersey + 8 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03743662" }, { "nct_id": "NCT05266612", "title": "Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "VG2025", "type": "DRUG" }, { "name": "Nivolumab Injection [Opdivo]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virogin Biotech Canada Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2022-11-09", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-10-15T20:42:49.001Z", "location_count": 2, "location_summary": "Gilbert, Arizona • Houston, Texas", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05266612" }, { "nct_id": "NCT02423863", "title": "In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Head and Neck Cancer", "Sarcoma", "Non-Melanoma Skin Cancers" ], "interventions": [ { "name": "Hiltonol", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Oncovir, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2015-03", "completion_date": "2020-08-31", "has_results": false, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-10-15T20:42:49.001Z", "location_count": 5, "location_summary": "Chevy Chase, Maryland • Easton, Maryland • Columbia, Missouri + 1 more", "locations": [ { "city": "Chevy Chase", "state": "Maryland" }, { "city": "Chevy Chase", "state": "Maryland" }, { "city": "Easton", "state": "Maryland" }, { "city": "Columbia", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02423863" }, { "nct_id": "NCT06177171", "title": "Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "BRCA1 Mutation", "BRCA2 Mutation", "BRCA Mutation", "PALB2 Gene Mutation", "Checkpoint Kinase 2 Gene Mutation", "ATM Gene Mutation" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "ASTX727", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Varun Monga, MBBS", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2024-02-07", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-15T20:42:49.001Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06177171" }, { "nct_id": "NCT04390399", "title": "Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "N-803", "type": "BIOLOGICAL" }, { "name": "Aldoxorubicin HCl", "type": "DRUG" }, { "name": "PD-L1 t-haNK", "type": "BIOLOGICAL" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" }, { "name": "Irinotecan liposome", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 328, "start_date": "2020-07-21", "completion_date": "2026-05-31", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-10-15T20:42:49.001Z", "location_count": 4, "location_summary": "El Segundo, California • Newport Beach, California • East Brunswick, New Jersey + 1 more", "locations": [ { "city": "El Segundo", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04390399" }, { "nct_id": "NCT05986240", "title": "Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML/MDS", "Acute Myeloid Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Danvatirsen", "type": "DRUG" }, { "name": "Danvatirsen + Venetoclax", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2024-05-08", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-15T20:42:49.001Z", "location_count": 2, "location_summary": "The Bronx, New York • Houston, Texas", "locations": [ { "city": "The Bronx", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05986240" }, { "nct_id": "NCT04144517", "title": "A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "Nemvaleukin Alfa", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mural Oncology, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2020-02-05", "completion_date": "2022-01-07", "has_results": true, "last_update_posted_date": "2024-10-16", "last_synced_at": "2026-10-15T20:42:49.001Z", "location_count": 7, "location_summary": "Miami, Florida • Atlanta, Georgia • Minneapolis, Minnesota + 3 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04144517" }, { "nct_id": "NCT04996004", "title": "A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leiomyosarcoma" ], "interventions": [ { "name": "Ontorpacept (TTI-621)", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2021-06-22", "completion_date": "2023-12-07", "has_results": true, "last_update_posted_date": "2024-12-11", "last_synced_at": "2026-10-15T20:42:49.001Z", "location_count": 23, "location_summary": "Santa Monica, California • Jacksonville, Florida • Tampa, Florida + 16 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04996004" } ] }